Drug profile · INN
abrocitinib
CIBINQO
abrocitinib (CIBINQO) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — abrocitinib
- US status
- approved
- Class
- Dermatologicals (D11)
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
abrocitinib (CIBINQO) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase JAK1 inhibitor
Primary target: Tyrosine-protein kinase JAK1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is abrocitinib?
abrocitinib (CIBINQO) is a tyrosine-protein kinase jak1 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for abrocitinib?
CIBINQO is a marketed brand name for abrocitinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of abrocitinib?
abrocitinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.